IT201600079773A1 - Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni. - Google Patents
Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni.Info
- Publication number
- IT201600079773A1 IT201600079773A1 IT102016000079773A IT201600079773A IT201600079773A1 IT 201600079773 A1 IT201600079773 A1 IT 201600079773A1 IT 102016000079773 A IT102016000079773 A IT 102016000079773A IT 201600079773 A IT201600079773 A IT 201600079773A IT 201600079773 A1 IT201600079773 A1 IT 201600079773A1
- Authority
- IT
- Italy
- Prior art keywords
- compositions
- derivatives
- preparation
- hyaluronic acid
- sulfate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102016000079773A IT201600079773A1 (it) | 2016-07-29 | 2016-07-29 | Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni. |
PCT/EP2017/069167 WO2018019996A1 (en) | 2016-07-29 | 2017-07-28 | Compositions containing hyaluronic acid oligosaccharides (ha4), chondroitin sulfate (cs2-4), and heparan sulfate (hs2-4), pentacyclic triterpenes and derivatives for curative medical use, and method for preparing the compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102016000079773A IT201600079773A1 (it) | 2016-07-29 | 2016-07-29 | Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni. |
Publications (1)
Publication Number | Publication Date |
---|---|
IT201600079773A1 true IT201600079773A1 (it) | 2018-01-29 |
Family
ID=58159222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT102016000079773A IT201600079773A1 (it) | 2016-07-29 | 2016-07-29 | Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni. |
Country Status (2)
Country | Link |
---|---|
IT (1) | IT201600079773A1 (it) |
WO (1) | WO2018019996A1 (it) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210015830A1 (en) * | 2017-12-28 | 2021-01-21 | Suntory Holdings Limited | Composition for inhibiting reactive oxygen species production |
IT202200004340A1 (it) * | 2022-03-08 | 2023-09-08 | Pharmaceutica San Marco S R L | Composizione o associazione di composti preferibilmente per l’uso nel trattamento di malattie nervose in particolare neurodegenerative, metodo per la preparazione di tale composizione o associazione di composti e suoi impieghi |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002009637A2 (en) * | 2000-07-28 | 2002-02-07 | Sinclair Pharmaceuticals Limited | Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome |
EP1611893A1 (en) * | 2003-03-25 | 2006-01-04 | Seikagaku Corporation | Remedy for nerve damage |
US20060239987A1 (en) * | 2005-04-22 | 2006-10-26 | Robert Foster | Nutritional composition and methods of making and using same |
EP1767211A1 (en) * | 2005-09-26 | 2007-03-28 | Glycoscience Laboratories, Inc. | Pharmaceutical agent containing hyaluronan as an active ingredient |
EP1994934A1 (en) * | 2006-12-05 | 2008-11-26 | Glycoscience Laboratories, Inc. | Therapeutic agent for degenerative arthritis |
EP2106798A1 (en) * | 2008-04-02 | 2009-10-07 | Nestec S.A. | Sulfated unsaturated disaccharidic chondroitin sulfate in connective tissue protection and repair |
WO2014076643A1 (en) * | 2012-11-13 | 2014-05-22 | ZAGGIA, Guerrino | Compound particularly for treating depression and anxiety |
WO2015088198A1 (ko) * | 2013-12-09 | 2015-06-18 | (주)뉴메딕 | 지속성을 갖는 히알루론산 겔 조성물 |
-
2016
- 2016-07-29 IT IT102016000079773A patent/IT201600079773A1/it unknown
-
2017
- 2017-07-28 WO PCT/EP2017/069167 patent/WO2018019996A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002009637A2 (en) * | 2000-07-28 | 2002-02-07 | Sinclair Pharmaceuticals Limited | Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome |
EP1611893A1 (en) * | 2003-03-25 | 2006-01-04 | Seikagaku Corporation | Remedy for nerve damage |
US20060239987A1 (en) * | 2005-04-22 | 2006-10-26 | Robert Foster | Nutritional composition and methods of making and using same |
EP1767211A1 (en) * | 2005-09-26 | 2007-03-28 | Glycoscience Laboratories, Inc. | Pharmaceutical agent containing hyaluronan as an active ingredient |
EP1994934A1 (en) * | 2006-12-05 | 2008-11-26 | Glycoscience Laboratories, Inc. | Therapeutic agent for degenerative arthritis |
EP2106798A1 (en) * | 2008-04-02 | 2009-10-07 | Nestec S.A. | Sulfated unsaturated disaccharidic chondroitin sulfate in connective tissue protection and repair |
WO2014076643A1 (en) * | 2012-11-13 | 2014-05-22 | ZAGGIA, Guerrino | Compound particularly for treating depression and anxiety |
WO2015088198A1 (ko) * | 2013-12-09 | 2015-06-18 | (주)뉴메딕 | 지속성을 갖는 히알루론산 겔 조성물 |
EP3081232A1 (en) * | 2013-12-09 | 2016-10-19 | New Medic Co., Ltd. | Hyaluronic acid gel composition having sustained release property |
Non-Patent Citations (3)
Title |
---|
KAGE MADOKA ET AL: "Hyaluronan tetrasaccharides stimulate ceramide production through upregulated mRNA expression of ceramide synthesis-associated enzymes", ARCHIVES OF DERMATOLOGICAL RESEARCH, SPRINGER, INTERNATIONAL, BERLIN, DE, vol. 308, no. 2, 28 December 2015 (2015-12-28), pages 95 - 101, XP035878866, ISSN: 0340-3696, [retrieved on 20151228], DOI: 10.1007/S00403-015-1615-6 * |
MADOKA KAGE ET AL: "Permeation of hyaluronan tetrasaccharides through hairless mouse skin: an in vitro and in vivo study", ARCHIVES OF DERMATOLOGICAL RESEARCH ; FOUNDED IN 1869 AS ARCHIV FÜR DERMATOLOGIE UND SYPHILIS, SPRINGER, BERLIN, DE, vol. 305, no. 1, 28 June 2012 (2012-06-28), pages 69 - 77, XP035156491, ISSN: 1432-069X, DOI: 10.1007/S00403-012-1252-2 * |
WANG JUN ET AL: "Hyaluronan Tetrasaccharide Exerts Neuroprotective Effect and Promotes Functional Recovery After Acute Spinal Cord Injury in Rats", NEUROCHEMICAL RESEARCH, PLENUM PRESS, NEW YORK, US, vol. 40, no. 1, 6 November 2014 (2014-11-06), pages 98 - 108, XP035433654, ISSN: 0364-3190, [retrieved on 20141106], DOI: 10.1007/S11064-014-1470-4 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018019996A1 (en) | 2018-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018076601A2 (pt) | formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação | |
CY1120885T1 (el) | Παραγωγα πυρρολο[3,2-d]πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων | |
CL2017003023A1 (es) | Anticuerpos anti-ctla-4 y métodos de uso de los mismos. | |
CL2018000705A1 (es) | Método de cristalización y biodisponibilidad | |
BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
BR112016003053A2 (pt) | micropartículas de células tronco e mirna | |
BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
BR112017016503A2 (pt) | conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo | |
BR112017014994A2 (pt) | formulação em pó nasal para o tratamento de hipoglicemia | |
BR112017026287A2 (pt) | composições de hidroxipropil beta-ciclodextrina e métodos | |
BR112017010426A2 (pt) | processo para preparar um pó inorgânico poroso. | |
BR112016022394A2 (pt) | Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável | |
BR112016029013A2 (pt) | aperfeiçoamento em composição nasal e método de utilização do mesmo | |
EP3773900A4 (en) | HINOKITIOL ANALOGUES, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
BR112017007748A2 (pt) | composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica | |
EP3409292A4 (en) | AQUEOUS STABILIZED COMPOSITION COMPRISING CHONDROITIN SULFATE AND HYALURONIC ACID | |
BR112018006870A2 (pt) | nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para a produção e o uso das mesmas | |
BR112018003455A2 (pt) | composição ou composição farmacêutica e uso da composição | |
EP3398971A4 (en) | OLIGOSACCHARIDE OF SULPHATED HEPARIN AND PREPARATION METHOD AND APPLICATION THEREOF | |
IT201600079773A1 (it) | Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni. | |
EP3311809A4 (en) | USE OF A PHARMACEUTICAL COMPOSITION IN THE PREPARATION OF A MEDICAMENT FOR PROMOTING CHONDROCYTE PRODUCTION | |
BR112017009850A2 (pt) | composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto | |
BR112017016388A2 (pt) | cenicriviroc para o tratamento da fibrose | |
EA201691246A1 (ru) | Комбинация гликозаминогликанов и циклодекстринов | |
IT201700110784A1 (it) | Composizioni farmaceutiche contenenti Acido Ialuronico e Carnosina e relativo uso |